All In Biotech

Drug Trial Radar · NCT04549597

Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia

Randomized Open-Label Study to Evaluate Tenapanor as the Core Therapy in the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Who Are Phosphate Binder Naive or on Phosphate Binders to Optimize Phosphorus Management

Last checked: Nov 19, 2026Latest source record: Mar 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 333 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

333

Actual

Start

Nov 20, 2020

Primary completion

Oct 13, 2021

Study completion Dec 1, 2021

Sponsor

Lead sponsor
ArdelyxIndustry
Sponsor type
Industry
First posted
Sep 16, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, open-label study to evaluate different methods of initiating tenapanor therapy in CKD patients on dialysis with hyperphosphatemia, when they are either phosphate binder naïve or on phosphate binder therapy. The objective to evaluate the effect of tenapanor alone or in combination with phosphate binders to achieve target serum phosphorus (s-P) levels of ≤5.5 mg/dL when tenapanor is administered as the core therapy (alone or in combination with phosphate binders) for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis.

Conditions

  • Chronic Kidney Disease Requiring Chronic Dialysis
  • Hyperphosphatemia

Interventions

  • TenapanorDrug

    Use of tenapanor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Effect of Tenapanor to Achieve Target s-P Levels of Less Than or Equal to 5.5 mg/dLTime frame: 10 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • South Florida Research Institute

    Lauderdale Lakes, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.